

September 04, 2024

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Please find enclosed herewith a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular dated July 13, 2023, an update on our wholly owned subsidiary company Glenmark Pharmaceuticals Inc., USA relating to settlement agreement with U.S. Department of Justice. The said update is provided in 'Annexure A'.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

Encl: as above

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Annexure – A

1. The details of any change in the status and / or any development in relation to such proceedings;

The Civil Division of the United States Department of Justice has concluded its False Claims Act and Anti-Kickback Statute investigation in a settlement (details below) with Glenmark Pharmaceuticals Inc., USA (“Glenmark”). The settlement agreement relates to the August 2023 Deferred Prosecution Agreement in the case of *United States v. Glenmark Pharmaceuticals Inc., USA*, 20-cr-200-RBS, in the United States District Court for the Eastern District of Pennsylvania and contains no new facts or admissions of liability by Glenmark.

2. In the case of litigation against key management personnel or its promoter or ultimate person in control, regularly provide details of any change in the status and / or any development in relation to such proceedings;

Not Applicable

3. In the event of settlement of the proceedings, details of such settlement including - terms of the settlement, compensation/penalty paid (if any) and impact of such settlement on the financial position of the listed entity.

Glenmark Pharmaceuticals Inc., USA (“Glenmark”) has agreed to pay to the United States 25,000,000 USD in six installments over five years, with interest on the settlement amount at a rate of 4.25 percent per annum from May 28, 2024. The settlement amount and interest on the settlement amount constitute restitution. As noted, the settlement does not contain any admission of liability by Glenmark, except to the extent already admitted by Glenmark in the August 2023 Deferred Prosecution Agreement.

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com